Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma TrialRakesh Popat, Matthew Streetly, Steve Schey et al.|British Journal of Haematology|2021Cited by 5
Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC)Rakesh Popat, Kwee Yong, James D. Cavenagh et al.|Blood|2014Cited by 1
RNA Sequencing of Newly Diagnosed Multiple Myeloma to Identify a Predictive Signature for Proteasome Inhibitor-Based TherapyJonathan Sive, Michael A. Chapman, John C. Ambrose et al.|Blood|2016Cited by 0
OUTCOMES IN PATIENTS ALLOCATED TO NO-ASCT BASED ON DEPTH OF RESPONSE: INITIAL RESULTS OF A PHASE 2 TRIAL ASSESSING THE IMPACT OF MINIMAL RESIDUAL DISEASE (MRD) IN PATIENTS WITH DEFERRED ASCT (PADIMAC)Rickin Popat, Ruth de Tute, Dunnya De‐Silva et al.|St George's Online Research Archive (St George's University of London)|2017Cited by 0
Outcomes of newly diagnosed multiple myeloma with deferred ASCT after achieving ≥VGPR following PAD induction in the Phase 2 PADIMAC studyWei Yee Chan, Kwee Yong, Nicholas Counsell et al.|Clinical Lymphoma Myeloma & Leukemia|2019Cited by 0